@article{7c790b808b8944539d696b0ae40f2db6,
title = "Guideline-Concordant Statin Therapy Use in Secondary Prevention: Should the Medical Community Wait for Divine Intervention?",
keywords = "atherosclerosis, predictors, prevention, secondary prevention, statins",
author = "Virani, {Salim S.} and Ballantyne, {Christie M.} and Petersen, {Laura A.}",
note = "Funding Information: Dr Virani has received institutional grant and research support from the Department of Veterans Affairs, The National Institutes of Health (NIH), the World Heart Federation, and The Jooma and Tahir Family; and has received an honorarium from the American College of Cardiology as Associate Editor of Innovations. Dr Ballantyne has received institutional grant and research support from Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, NIH, the American Heart Association, and the American Diabetes Association; and has provided consulting for Abbott Diagnostics, Althera, Amarin, Amgen, Arrowhead, AstraZeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo. Dr Petersen has reported that she has no relationships relevant to the contents of this paper to disclose.",
year = "2022",
month = may,
day = "10",
doi = "10.1016/j.jacc.2022.02.042",
language = "English",
volume = "79",
pages = "1814--1817",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "18",
}